regadenoson

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Heart Failure, Diastolic

Conditions

Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension

Trial Timeline

Nov 1, 2015 → Jan 21, 2020

NCT ID

NCT02589977

About regadenoson

regadenoson is a approved stage product being developed by Astellas Pharma for Heart Failure, Diastolic. The current trial status is completed. This product is registered under clinical trial identifier NCT02589977. Target conditions include Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure, Diastolic were approved

Approved (20) Terminated (3) Active (0)

✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved

✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved

✅ConivaptanAstellas PharmaApproved

✅RegadenosonAstellas PharmaApproved

✅Regadenoson + GadoliniumAstellas PharmaApproved

✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

✅Dapagliflozin 10mg TabAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02697877	Pre-clinical	Completed	Feb 1, 2016	Jul 1, 2018	Coronary Artery Disease
NCT02589977	Approved	Completed	Nov 1, 2015	Jan 21, 2020	Heart Failure, Diastolic
NCT02220634	Pre-clinical	Terminated	Aug 1, 2014	May 25, 2017	Pulmonary Hypertension
NCT01969916	Pre-clinical	Completed	Jun 1, 2014	Jun 1, 2018	Coronary Artery Disease
NCT01779869	Approved	Completed	Jan 1, 2013	Jun 1, 2015	Ischemic Heart Disease
NCT01618669	Phase 3	Completed	Jun 1, 2012	Dec 1, 2014	Coronary Artery Disease (CAD)
NCT01446094	Approved	UNKNOWN	Aug 1, 2011	Jun 1, 2018	Coronary Artery Disease
NCT01334918	Phase 2	Completed	Apr 26, 2011	Jul 2, 2012	Coronary Artery Disease (CAD)
NCT01021618	Pre-clinical	Completed	Jan 1, 2010	Mar 1, 2012	Coronary Artery Disease
NCT01026012	Pre-clinical	Completed	Dec 1, 2009	Sep 1, 2010	Cardiac Function
NCT00881218	Phase 1	Completed	Jun 1, 2009	Dec 1, 2011	Ischemic Heart Disease
NCT00837369	Phase 1	Completed	Apr 7, 2009	Dec 1, 2011	Coronary Artery Disease
NCT00871260	Approved	Completed	Apr 1, 2009	Jun 4, 2014	Coronary Disease
NCT00857792	Pre-clinical	Completed	Mar 1, 2009	Jan 1, 2013	Coronary Disease

Competing Products

20 competing products in Heart Failure, Diastolic

See all competitors

Product	Company	Stage	Hype Score
mRNA-0184	Moderna	Phase 1	0
IV diuretic	Nuwellis	Pre-clinical	16
IV Loop Diuretics	Nuwellis	Pre-clinical	23
Stepped pharmacologic care	Nuwellis	Phase 3	30
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	8
TRV120027 + Normal Saline	Trevena	Phase 1	19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	25
TRV120027 + Placebo	Trevena	Phase 1/2	22
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	25
INXN-4001	Precigen	Phase 1	23
LY3461767 + Placebo	Eli Lilly	Phase 1	29
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	43
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	32
Olmesartan	Daiichi Sankyo	Phase 3	40
Carperitide + Placebo	Daiichi Sankyo	Phase 2	35
Edoxaban	Daiichi Sankyo	Pre-clinical	22
Regadenoson	Astellas Pharma	Phase 1	29
Advagraf + Prograf	Astellas Pharma	Phase 2	35